Literature DB >> 17144675

DNA interactions of pH-sensitive, antitumor bis(aminoalcohol)dichloroplatinum(II) complexes.

Stefanie Zorbas-Seifried1, Christian G Hartinger, Kristof Meelich, Mathea Sophia Galanski, Bernhard K Keppler, Haralabos Zorbas.   

Abstract

(SP-4-2)-Bis(2-aminoethanol)dichloroplatinum(II) (KP1356) and (SP-4-2)-bis[(R)-(-)-2-aminobutanol)]dichloroplatinum(II) (KP1433) are promising cytotoxic agents capable of changing their chemical structure depending on the pH value. On the basis of this, they are supposed to be active only in or preferentially in hypoxic tumors with low pH. In this study, we investigated the kinetics of changes of the DNA secondary structure, of the DNA modification degree, and of the formation of interstrand cross-links caused by these complexes in comparison to the parental compound cis-diamminedichloroplatinum(II) (cisplatin). All examinations were performed at physiological pH 7.4 and at pH 6.0 mimicking the acidified environment of many tumor tissues. In general, cisplatin displayed a higher reactivity accompanied by more pronounced DNA compaction, untwisting, and formation of interstrand cross-links at both pH values. Additionally, it was shown for the first time that cisplatin generates interstrand cross-links faster at pH 6.0 than at 7.4. However, the difference between pH 7.4 and 6.0 was much larger for KP1356 and KP1433 than for cisplatin, since they were essentially nonreactive and induced almost no secondary structures at pH 7.4, as contrasted to cisplatin. Our data suggest that formed adducts, i.e., intra- and/or interstrand cross-links, may be the sole cause of the cytotoxicity of KP1356 and KP1433 at pH 6.0. The results of this study may stimulate and contribute to further improvement of these novel, specific cytotoxic drugs that are anticipated to exert their full power in the tumor while being reasonably inactive in normal tissue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17144675     DOI: 10.1021/bi061063i

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Authors:  Michael Groessl; Yury O Tsybin; Christian G Hartinger; Bernhard K Keppler; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-03-07       Impact factor: 3.358

2.  DNA Polyplexes as Combinatory Drug Carriers of Doxorubicin and Cisplatin: An in Vitro Study.

Authors:  Han Chang Kang; Hana Cho; You Han Bae
Journal:  Mol Pharm       Date:  2015-07-13       Impact factor: 4.939

3.  Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes.

Authors:  Seied Mojtaba Valiahdi; Alexander E Egger; Walter Miklos; Ute Jungwirth; Kristof Meelich; Petra Nock; Walter Berger; Christian G Hartinger; Markus Galanski; Michael A Jakupec; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2013-01-26       Impact factor: 3.358

4.  Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial Quinolones.

Authors:  Jakob Kljun; Anna K Bytzek; Wolfgang Kandioller; Caroline Bartel; Michael A Jakupec; Christian G Hartinger; Bernhard K Keppler; Iztok Turel
Journal:  Organometallics       Date:  2011-04-06       Impact factor: 3.876

5.  The Application of Reversible Intramolecular Sulfonamide Ligation to Modulate Reactivity in Organometallic Ruthenium(II) Diamine Complexes.

Authors:  Samuel A Kemp; Timothy J Prior; Huguette Savoie; Ross W Boyle; Benjamin S Murray
Journal:  Molecules       Date:  2020-01-07       Impact factor: 4.411

6.  A pH responsive complexation-based drug delivery system for oxaliplatin.

Authors:  Bin Li; Zhao Meng; Qianqian Li; Xiayang Huang; Ziyao Kang; Huajin Dong; Junyi Chen; Ji Sun; Yansheng Dong; Jian Li; Xueshun Jia; Jonathan L Sessler; Qingbin Meng; Chunju Li
Journal:  Chem Sci       Date:  2017-04-19       Impact factor: 9.825

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.